全文获取类型
收费全文 | 111篇 |
免费 | 8篇 |
国内免费 | 1篇 |
专业分类
妇产科学 | 1篇 |
基础医学 | 3篇 |
临床医学 | 6篇 |
内科学 | 50篇 |
神经病学 | 4篇 |
外科学 | 46篇 |
综合类 | 1篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 1篇 |
中国医学 | 2篇 |
肿瘤学 | 4篇 |
出版年
2020年 | 2篇 |
2018年 | 5篇 |
2017年 | 2篇 |
2016年 | 2篇 |
2014年 | 2篇 |
2013年 | 3篇 |
2012年 | 8篇 |
2011年 | 10篇 |
2010年 | 3篇 |
2009年 | 4篇 |
2008年 | 14篇 |
2007年 | 15篇 |
2006年 | 14篇 |
2005年 | 11篇 |
2004年 | 5篇 |
2003年 | 3篇 |
2002年 | 5篇 |
2001年 | 5篇 |
1999年 | 1篇 |
1992年 | 2篇 |
1990年 | 1篇 |
1988年 | 1篇 |
1984年 | 1篇 |
1937年 | 1篇 |
排序方式: 共有120条查询结果,搜索用时 15 毫秒
1.
Bruno Fautrel Thao Pham Gaël Mouterde Xavier Le Loët Philippe Goupille Francis Guillemin Philippe Ravaud Alain Cantagrel Maxime Dougados Xavier Puchal Jean Sibilia Martin Soubrier Xavier Mariette Bernard Combe pour le Club rhumatismes et inflammation pour la Socit franaise de rhumatologie 《Revue du Rhumatisme》2007,74(12):1301-1311
2.
Mekinian A Néel A Sibilia J Cohen P Connault J Lambert M Federici L Berthier S Fiessinger JN Godeau B Marie I Guillevin L Hamidou M Fain O;Club Rhumatismes et Inflammation French Vasculitis Study Group Société Nationale Française de Médecine Interne 《Rheumatology (Oxford, England)》2012,51(5):882-886
3.
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases 总被引:16,自引:0,他引:16
Gottenberg JE Guillevin L Lambotte O Combe B Allanore Y Cantagrel A Larroche C Soubrier M Bouillet L Dougados M Fain O Farge D Kyndt X Lortholary O Masson C Moura B Remy P Thomas T Wendling D Anaya JM Sibilia J Mariette X;Club Rheumatismes et Inflammation 《Annals of the rheumatic diseases》2005,64(6):913-920
OBJECTIVE: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. METHODS: 866 rheumatology and internal medicine practitioners were contacted by e-mail to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated. RESULTS: In all, 43 of 49 cases could be analysed, including 14 with rheumatoid arthritis (RA), 13 with systemic lupus erythematosus (SLE), six with primary Sjogren's syndrome (pSS), five with systemic vasculitis, and five with other autoimmune diseases. Rituximab was prescribed for lymphoma in two patients with RA and two with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. The mean follow up period was 8.3 months (range 2 to 26). There were 11 adverse events in 10 patients and treatment had to be discontinued in six. Efficacy was observed in 30 patients (70%): RA 11, SLE 9, pSS 5, vasculitis 2, antisynthetase syndromes 2, sarcoidosis 1. The mean decrease in corticosteroid intake was 9.5 mg/d (range 0 to 50) in responders. Seven patients experienced relapse after mean 8.1 months (5 to 15). Three patients died because of refractory autoimmune disease. CONCLUSIONS: Despite absence of marketing authorisation, rituximab is used to treat various refractory autoimmune diseases in daily rheumatological practice. This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis. 相似文献
4.
Fontaine D Bauchet L Capelle L;Club de Neuro Oncologie de la Société Française de Neurochirurgie 《Neuro-Chirurgie》2005,51(2):136-141
OBJECTIVE: This second part of the inquiry of the NeuroOncolgy Group of the French Neurosurgical Society was undertaken to evaluate the involvement of French neurosurgeons in brain tumor research. METHODS: In December 2003, A questionnaire called "Census of current and future research studies about brain tumors in your center" has been mailed to every French neurosurgical department. For each protocol, responders were asked to mention: the title of the protocol, its mono- or multi-centric design, the name of the principal investigator, the name of the neurosurgeon(s) involved in the study, the topic of the study (epidemiology, imaging, biology, genetics, therapy), tumor histology, financial support, and partners. RESULTS: Twenty-three centers responded. Sixty-three studies were described. There were 6 epidemiological studies, 7 imaging studies, 27 biological or genetic studies and 15 clinical trials concerning glial tumors, and 8 biological studies concerning non glial tumors. Each study is described in the text with the data previously mentioned. CONCLUSION: Despite the fact that several centers did not answer, this inquiry confirmed the strong involvement of French neurosurgeons in brain tumor research. 相似文献
5.
Capsule enteroscopy vs. other diagnostic procedures in diagnosing obscure gastrointestinal bleeding: a cost-effectiveness study 总被引:2,自引:0,他引:2
Marmo R Rotondano G Rondonotti E de Franchis R D'Incà R Vettorato MG Costamagna G Riccioni ME Spada C D'Angella R Milazzo G Faraone A Rizzetto M Barbon V Occhipinti P Saettone S Iaquinto G Rossini FP;Club Italiano Capsula Endoscopica - CICE 《European journal of gastroenterology & hepatology》2007,19(7):535-542
BACKGROUND: Capsule enteroscopy is considered the gold standard for evaluating patients with obscure gastrointestinal bleeding. The costs of capsule enteroscopy examination, however, make it uncertain whether the clinically relevant diagnostic gain is also associated with cost savings. AIM: To evaluate the incremental cost-effectiveness ratio of capsule enteroscopy in patients with obscure gastrointestinal bleeding. METHODS: Retrospective study was carried out in nine Italian gastroenterology units from 2003 to 2005. Data on 369 consecutive patients with obscure gastrointestinal bleeding were collected. The diagnostic yield of capsule enteroscopy vs. other imaging procedures was evaluated as a measure of efficacy. The values of Diagnosis Related Group 175 (euro 1884.00 for obscure-occult bleeding and euro 2141.00 for obscure-overt bleeding) were calculated as measures of economic outcomes in the cost analysis. RESULTS: Obscure and occult gastrointestinal bleeding was recorded in 177 patients (48%) with a mean duration of anemia history of 17.6+/-20.7 months. Among patients, 60.9% had had at least one hospital admission, 21.2% at least two, and 1.2% of obscure bleeders up to nine admissions. Overall, 58.4% of patients had positive findings with capsule enteroscopy compared with 28.0% with other imaging procedures (P<0.001). The mean cost of a positive diagnosis with capsule enteroscopy was euro 2090.76 and that of other procedures was euro 3828.83 with a mean cost saving of euro 1738.07 (P<0.001) for one positive diagnosis. CONCLUSIONS: Capsule enteroscopy is a cost-saving approach in the evaluation of patients with obscure gastrointestinal bleeding. 相似文献
6.
Fontaine H Petitprez K Roudot-Thoraval F Trinchet JC;Association francaise pour l'etude du foie;Club de reflexion des cabinets et groupes d'hepato-gastro-enterologue;College national des generalistes enseignants;Groupe francophone d'hepatologie gastro-enterologie et nutrition pediatriques;Societe francaise de biologie clinique;Societe francaise de radiologie;Societe nationale francaise de gastro-enterologie 《Gastroentérologie clinique et biologique》2007,31(5):504-509
7.
8.
9.
Gorwood P Pouchot J Vinceneux P Puéchal X Flipo RM De Bandt M Adès J;Club Rhumatisme et Inflammation 《Schizophrenia Research》2004,66(1):21-29
There is wide evidence for a decreased risk of rheumatoid arthritis in patients with schizophrenia. Nevertheless, very few studies have looked at the risk of schizophrenia in a group of patients with rheumatoid arthritis. We prospectively investigated, with the SCL-90R, 220 consecutive outpatients with rheumatoid arthritis and 196 consecutive outpatients with various medical conditions, half of them suffering from psoriatic arthritis (a medical condition close to rheumatoid arthritis). The SCL-90R appears to be a valuable tool to distinguish patients with schizophrenia from the outpatients of our sample, the former having more "paranoid ideation" (p = 0.004) and more "psychoticism" (p < 0.001) than the latter. The "paranoid ideation" dimension was significantly lower (25% decrease) in the sample of patients with rheumatoid arthritis compared to the combined control group (p = 0.005), ratings under the median value being more frequent in the former group (p = 0.025). Confounding factors might not explain this difference according to the regression logistic analysis performed. As patients with rheumatoid arthritis have a lower score of paranoid ideation than controls in our sample, even after controlling for age, gender and severity of the disease, these data represent further evidence for a decreased risk of schizophrenia in individuals with rheumatoid arthritis. 相似文献
10.